BTIG Maintains Buy on Nurix Therapeutics, Raises Price Target to $32
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
BTIG analyst Jeet Mukherjee maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $30 to $32.
BTIG analyst Jeet Mukherjee maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $30 to $32.